Andersson S, Russell DW (1990) Structural and biochemical properties of cloned and expressed human and rat steroid 5a-reductases. Proc Natl Acad Sci USA 87:3640-3644 Berges RR, Vukanovicm, J Epstein, JI CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT (1995) Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Can Res 1:473-480 Biswas MG, Russell DW (1997) Expression cloning and characterization of oxidative 17p- and 3a-hydroxysteroid dehydrogenases from rat and human prostate. J Biol Chem 272:1595915966

Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474-479 Bonkhoff H (1998) Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis proliferation and androgen receptor status. Prostate Suppl 8:18-22 Bonkhoff H, Remberger K (1996) Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth - a stem cell model. Prostate 28:98-106 Bonkhoff H, Stein U, RembergerK (1994a) Multidirectional differentiation in the normal hyperplastic and neoplastic human prostate: simultaneous demonstration of cell-specific epthelial markers. Hum Pathol 25:42-46 Bonkhoff H, Stein U, Remberger K (1994b) The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24:114-118 Bonkhoff H, Stein U, Aumuller G, Remberger K (1996) Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29:261267

Bonkhoff H, Fixemer T, Remberger K (1998) Relation between Bcl-2 cell proliferation and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 34: 251-258

Boyd E (1962) Growth including reproduction and morphological development. In: Altman and Dittmer (eds) Biological Handbooks Federation of American Societies for Experimental Biology, Washington DC, pp 346-348 Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, Masters JR (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer: J Pathol 198:237-244

Bruchovsky N, Wilson JD (1968) The conversion of testosterone in 5 a-androstan-17-ß-ol-3-one by the rat prostate in vivo and in vitro. J Biol Chem 243:2012-2021 Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD (2001) Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7:1273-1281 Chadli A, Bouhouche I, Sullivan W, Stensgard B, McMahon N, Catelli MG, Toft DO (2000) Dimerization and N-terminal domain proximity underlie the function of the molecular chap-erone heat shock protein 90. Proc Natl Acad Sci USA 97:12524-12529 Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ (1996) Expression of G1 cyclins cyclin-dependent kinases and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 7:1571-1578 Chen S, Song CS, Lavrovsky Y, Bi B, Vellanoweth R, Chatterjee B, Roy AK (1998) Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. Mol Endocrinol 12:1558-1566 Chopra DP, Grignon DJ, Joiakim A, Mathieu PA, Mohamed A, Sakr WA, Powell IJ, Sarkar FH (1996) Differential growth factor responses of epithelial cell cultures derived from normal human prostate benign prostatic hyperplasia and primary prostate carcinoma. J Cell Physiol 169:269-280

Coffey DS (1992) The molecular biology endocrinology and physiology of the prostate and seminal vesicles. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds) Campbell's Textbook of Urology. Saunders, Philadelphia, pp 221-266 Collins AT, Habib FK, Maitland NJ, Neal DE (2001) Identification and isolation ofhuman prostate epithelial stem cells based on a2ß1-integrin expression. J Cell Sci 114:3865-3872 Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y (1987) The endocrinology and developmental biology of the prostate. Endocr Rev 8:338-362 De Marzo AM, Meeker AK, Epstein JI, Coffey DS (1998a) Prostate stem cell compartments: expression of the cell cycle inhibitor p27kip1 in normal hyperplastic and neoplastic cells. Am J Pathol 153:911-919

De Marzo AM, Nelson WG, Meeker AK, Coffey DS (1998b) Stem cell features of benign and malignant prostate epithelial cells. J Urol 160:2381-2392 De Marzo AM, Marchi VL, Epstein JI, Nelson WG (1999) Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 155:1985-1992 De Marzo AM, Putzi MJ, Nelson WG (2001) New concepts in the pathology of prostatic epithelial carcinogenesis. Urology 57(Suppl 1):103-114 Denmeade SR, Lin XS, Isaacs JT (1996) Role of programmed (apoptotic) cell death during the progression and therapy of prostate cancer. Prostate 28:251-265 Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G, Klocker H (2002) Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9:117-125

English HF, Santen RJ, Isaacs JT (1987) Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11:229-242 Fixemer T, Remberger K, Bonkhoff H (2003) Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue premalignant changes and in primary metastatic and recurrent prostatic adenocarcinoma. Prostate 54:79-87 Foley CL, Kirby RS (2003) 5 alpha-reductase inhibitors: what's new? Curr Opin Urol 13:31-37 Frasier SD, Gafford F, Horton RD (1969) Plasma androgens in childhood and adolescence. J Clin

Endocrinol Metab 29:1404-1408 Gao J, Isaacs JT (1998) Development of an androgen receptor null model for identifying the site of initiation for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. Cancer Res 58:3299-3306 Gao J, Arnold JT, Isaacs JT (2001) Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61:5038-5044 Geck P, Szelei J, Jimenez J, Lin TM, Sonnenschein C, Soto AM (1997) Expression of novel genes linked to the androgen-induced proliferative shutoff in prostate cancer cells. J Steroid Biochem Mol Biol 63:211-218

GerdesMJ, Larsen M, McBrideL, Dang TD, LuB, Rowley DR (1998) Localization of transforming growth factor-beta1 and type II receptor in developing normal human prostate and carcinoma tissues. J Histochem Cytochem 46:379-388 Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Van Woude GF, Knudsen BS (2001) Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 159:579-590 Gottlieb B, Vasiliou DM, Lumbroso R, Beitel LK, Pinsky L, Trifiro MA (1999) Analysis of exon

1 mutations in the androgen receptor gene. Hum Mutat 14:527-539 Hayward SW, Del Buono R, Deshpande N, Hall PA (1992) A functional model of adult human prostate epithelium: The role of androgens and stroma in architectural organization and the maintenance of differentiated secretory function. J Cell Sci 102:361-372 He B, Bowen NT, Minges JT, Wilson EM (2001) Androgen-induced NH2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 276:42293-42301

Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1996) Androgen receptor status of lymph node metastases from prostate cancer: Prostate 28:129-135 Hudson DL, O'Hare M, Watt FM, Master JR (2000) Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 80:1243-1250 Huggins C, Johnson MA (1947) Carcinoma of the bladder and prostate. JAMA. 135:1146-1152 Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I, Helin HJ, Janne OA, Vihinen M, Palvimo JJ, Koivisto PA (2002) Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest 82:15911598

Imperato-McGinley J, Peterson RE, Leshin M, Griffen JE, Cooper G, Draghi S, Berenyi M, Wilson JD (1980) Steroid 5a-reductase deficiency in a 65-year-old male pseudohermaphrodite: The natural history ultrastructure of the testes and evidence for inherited enzyme heterogeneity. J Clin Endocrinol Metab 50:15-21

Isaacs JT (1987) Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In: Rogers CH, Coffey DS, Cunha G, Grayhack J, Hinman F, Horton R (eds) Benign prostatic hyperplasia Report No INH 87-2881. Department of Health and Human Services, National Institutes of Health Bethesda MD pp 85-94 Isaacs JT (1994) Role of androgens in prostatic cancer. Vitam Horm 49:433-502 Isaacs JT (1999) The biology of hormone refractory prostate cancer: Why does it develop? In: Urologic Clinics of North America: WB Saunders Company, Philadelphia PA, Vol 26 pp 263-273

Isaacs JT, Coffey DS (1989) Etiology of BPH. Prostate, Supplement 2:33-50 Isaacs JT (1984a) Common characteristics of human and canine benign prostatic hyperplasia. In: Kimball FA (ed), New approaches to the study of benign prostatic hyperplasia. AR Liss Inc New York, pp 217-234

Isaacs JT (1984b) Antagonistic effect of androgens on prostatic cell death. Prostate 5:545-557 Isaacs JT, Brendler CB, Walsh PC (1983) Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. J Clin Endocrinol Metab 56:139-146 Isaacs JT, McDermott IR, Coffey DS (1979) The identification and characterization of a new C19O3 steroid metabolite in the rat ventral prostate: 5a-androstane-3ß 6a-17ß-trial. Steroids 33:639-675

Jain A, Lam A, Vivanco I, Carey MF, Reiter RE (2002) Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 16:2323-2337 Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics 2003.

CA Cancer J Clin 53:5-26 Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW (1992) Genetic and pharmacologic evidence for more than one human steroid 5a-reductase. J Clin Invest 89:293300

Jenkins EP, Hsieh C-L, Milatovich A, Normington K, Berman DM, Franke U, Russel PW (1991) Characterization and chromosomal mapping of a human steroid 5 a-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 11:1102-1112 Joseph IB, Nelson JB, Denmeade SR, Isaacs JT(1997) Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 3:2507-2511 Kang Z, Pirskanen A, Janne OA, Palvimo JJ (2002) Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem 277:48366-48371 Kasai S, Sugimura K, Matsumoto K, Nozomu N, Kishimoto T, Nakamura T (1996) Hepatocyte growth factor is a paracrine regulator of rat prostate epithelial growth. Biochem Biophys Res Communications 228:646-652 Kurita T, Wany YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GR (2001) Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8:192-200 Kyprianou N, English H, Isaacs JT (1990) Programmed cell death during regression of the PC-82

human prostate cancer following androgen ablation. Cancer Res 50:3748-3752 Kyprianou N, English HF, Isaacs JT (1988) Activation of a Ca2+-Mg2+ -dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 13:103-117 Kyprianou N, Isaacs JT (1987) Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept. Prostate 11:41-50

Kyprianou N, Isaacs JT (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122:552-562 Kyprianou N, Isaacs JT (1989) Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3:1515-1522 Labrie F, Sugimoto Y, Luu-The Simand J, Lachance YI, Bachuarov D, Leblanc J, Durocher F, Paquet N (1992) Structure of human type II 5a-reductase gene. Endocrinology 131:15711573

Levy MA, Brandt M, Heys JR, Holt DA, Metcalf BW (1990) Inhibition of rat liver steroid 5a-reductase by 3-androstene-3-carboxylic acids: Mechanism of enzyme-inhibitor interaction. Biochemistry 29:2815-2824 Liao S, Leong T, Tymocyko JL (1972) Structural recognition in interactions of androgens and receptor proteins and in their association with nuclear components. J Steroid Biochem 3:401407

Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, Asgari K, Freije D, van Rees B, Gage WR, Bova GS, Isaacs WB, Brooks JD, de Weese TL, De Marzo AM, Nelson WG (2001) GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 159:1815-1826 Ling MT, Chan KW, Choo CK (2001) Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol 170:287-296 Linja MJ, Savinainen KJ, Saramaki OR, Tammela TLJ, Vessella RL, Visakorpi T (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555 Lissbrant IF, Lissbrant E, Damber JE, Bergh A (2001) Blood vessels are regulators of growth diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35:437452

Litvinov IV, DeMarzo AM, Isaacs JT (2003) Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88:2972-2982 Liu AY, Peehl DM (2001) Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell Tissue Res 305:389-397 Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, BanderNH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629-3634 Lu L, Schulz H, Wolf DA (2002) The F-box protein SKP2 mediates androgen control of p27

stability in LNCaP human prostate cancer cells. BMC Cell Biology 3:22 Lu W, Luo Y, Kan M, McKeehan WL (1999) Fibroblast growth factor-10: second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 274:12827-12834 Mann T, Mann CL (1981) Male reproductive function and semen. Springer-Verlag New York Martikainen P, Kyprianou N, Isaacs JT (1990) Effect of transforming growth factor-ß1 on proliferation and death of rat prostatic cells. Endocrinology 127:2963-2968 McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML (1992) Expression of the protooncogene Bcl-2 in the prostate and association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944 McNeal JE, Bostwick DG (1986) Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 17:64-71

McNeal JE, Redwine EA, Freiha FS, Stamey TA (1988) Zonal distribution of prostatic adenocar-

cinoma. Am J Surg Pathol 12:897 Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, DeMarzo AM (2002) Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 62:6406-6409 Mitchell SH, Murtha PE, Zhang S, Zhu W, Young CYF (2000) An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol 168:89-99

Moore RA (1944) Benign hypertrophy and carcinoma of the prostate: Occurrence and experimental production in animals. Surgery 16:152-167 Normington K, Russell DW (1992) Tissue distribution and kinetic characteristics of rat steroid

5a-reductase isozymes. J Biol Chem 267:19548-19554 Ornstein DK, Cinquanta M, Weiler S, Duray PH, Emmert-Buck MR, Vocke CD, Linehan WM, Ferretti JA (2001) Expression studies and mutational analysis of the androgen regulated home-obox gene NKX31 in benign and malignant prostate epithelium. J Urol 165:1329-1334 Peehl Dmand, Sellers RG (1997) Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Experimental Cell Res 232:208-215 Planz B, Aretz HT, Wang Q, Tabatabaei S, Kirley SD, Lin CW, McDougal WS (1999) Immunolo-calization of the keratinocyte growth factor in benign and neoplastic human prostate and is relation to androgen receptor. Prostate 41:233-242 Plymate SR, Tenover JS, Brenner WJ (1989) Circadian variation in testosterone sex hormone-binding globulin and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly man. J Androl 10:366-371 Price D, Williams-Ashman GH (1961) The accessory reproductive glands of mammals In: Young WC (ed) Sex and internal secretions 3rd ed. Williams & Wilkins, Baltimore MD, pp 366488

Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM (2003) Human type 3 3a-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144:2922-2932 Robinson EJ, Neal DE, Collins AT (1998) Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostate epithelium. Prostate 37:149-160 Rumpold H, Heinrich E, Untergasser G, Hermann M, Pfister G, Plas E, Berger P (2002) Neuroendocrine differentiation ofhuman prostatic primary epithelial cells in vitro. Prostate 53:101-108 Sampson ER, Yeh SY, Chang HC, Tsai MY, Wang X, Ting HJ, Chang C (2001) Identification and characterization of androgen receptor associated coregulators in prostate cancer cells. J Biol Regul Homeost Agents 15:123-129 Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR (1996) Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271:7043-7051

Shang Y, Myers M, Brown M (2002) Formation of the androgen receptor transcription complex. Mol Cell 9:601-610

Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769-1775

Silver SJ, Balmacoda J, Borrero C (1988) Pregnancy with sperm aspiration from the proximal head of the epididymis: a new treatment for congenital absence of the vas deferens. Fertil Steril 50:525-530

Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkuma B, Balk SP (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515

Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B Study 9663 (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21:2673-2678

Thigpen AE, Davis DL, Milatovich A, Mendonca BD, Imperato-McGinley J, Griffin J, Franke U, Wilson JD, Russel DW (1992) Molecular genetics of steroid 5a-reductase 2 deficiency. J Clin Invest 90:799-809

Torn S, Nokelainen P, Kurlela R, Pulkka A, Menjivar M, Ghosh S, Coca-Prados M, Peltoketo H, Isomaa V, Vihko P (2003) Production purification and functional analysis of recombinant human and mouse 17ß-hydroxysteroid dehydrogenase type 7. Biochem and Biophys Res Commun 305:37-45

Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J (2000) Involvement of p27Kip1 in G1 arrest by high dose 5a-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 19:670-679

Van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J (2000) Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 80:1251-1258

Van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J (2002) Intermediate cells in normal and malignant prostate epithelium express c-MET: Implications for prostate cancer invasion. Prostate 51:98-107

Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA (1992) Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 52:6182-6187

Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M (2001) Androgen-driven prostate epithelial cell proliferation anddifferentiation in vivo involve the regulation ofp27. Mol Endocrinol 15:765-782

Watabe T, Lin M, Ide H, Donjacour AA, Cunha GR, Witte ON, Reiter RE (2002) Growth regeneration and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci USA 99:401-406

Watt F, Martorana A, Brookes DE, Ho T, Kingsley E, O'Keefe DS, Russell PJ, Heston WD, Molloy PL (2001) A tissue-specific enhancer of the prostate-specific membrane antigen gene folh1. Genomics 73:243-254

Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jenson EV, Nilsson S, Warner M, Gustafsson J-A(2001)A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98:6330-6335

Weihua Z, Lathe R, Warner M, Gustafsson J-A (2002) An endocrine pathway in the prostate ERß AR 5a-androstane-3ß 17ß-diol and CYP7B1 regulates prostate growth. Proc Natl Acad Sci USA 99:13589-13594

Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL (2002) Androgen induction of in vitro prostate cell differentiation. Cell Growth & Differ 13:1-11 Wikstrom P, Westin P, Stattin P, Damber JE, Bergh A (1999) Early castration-induced upreg-ulation of transforming growth factor beta1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate 38:268-277

Wilson JD (1984) The endocrine control of sexual differentiation. Harvey Lect 79:145-172 Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai M-J, O'Malley BW (1998) Partial hormone resistance in mice with disruption of the steroid receptor coativator-1 (SRC-1) gene. Science 279:1922-1925 Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW (2002) Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitorp27 and PTEnandwith reduced recurrence-free survival. Clin Cancer Res 8:3419-3426 Yang G, Timme TL, Park SH, Thompson TC (1997) Transforming growth factorbeta 1 transduced mouse prostate reconstitutions: I Induction of neuronal phenotypes. Prostate 33:151-156 Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 6:1008-1013

Zelivianski S, Igawa T, Lim S, Taylor R, Lin M (2002) Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter Oncogene 21:36963705

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment